Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection

Background: Ending the global COVID-19 pandemic requires efficacious therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nevertheless, the emerging Omicron sublineages largely escaped the neutralization of current authorized monoclonal antibody therapies. Here we report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Huabing, Chen, Yuxin, Jiang, Dongcheng, Feng, Xiaoli, Xu, Ying, Wei, Jiayu, Zou, Qingcui, Yang, Qiaojiang, Chen, Jihong, Jiang, Xiaoling, Qin, Chunling, Huang, Zhenzhen, Wu, Chongbing, Zhou, Ying, Li, Minghua, Yin, Liusong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108555/
https://www.ncbi.nlm.nih.gov/pubmed/37077474
http://dx.doi.org/10.1093/abt/tbad003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108555/
https://www.ncbi.nlm.nih.gov/pubmed/37077474
http://dx.doi.org/10.1093/abt/tbad003

Ejemplares similares